Aldeyra Therapeutics (ALDX) Misses Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. CRWD
4. ON
5. VRTX
6. INSP
7. RXRX
8. CHKP
9. HNGE
10. MTCH

Go back to Aldeyra Therapeutics (ALDX) Misses Q2 EPS by 3c

Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update

August 9, 2018 7:30 AM EDT

LEXINGTON, Mass., Aug. 9, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for the second quarter ended June 30, 2018 and provided a corporate update.

"As our lead product candidate reproxalap has advanced to four late-stage clinical programs, our development pipeline continues to grow, and now features a number of novel compounds across multiple diseases and mechanisms of action," stated Todd C. Brady, M.D., Ph.D., President... More